Understanding bladder cancer death See editorial on pages 914-7, this issue.
dc.contributor.author | Morris, David S. | en_US |
dc.contributor.author | Weizer, Alon Z. | en_US |
dc.contributor.author | Ye, Zaojun | en_US |
dc.contributor.author | Dunn, Rodney L. | en_US |
dc.contributor.author | Montie, James E. | en_US |
dc.contributor.author | Hollenbeck, Brent K. | en_US |
dc.date.accessioned | 2009-03-03T20:09:24Z | |
dc.date.available | 2010-04-14T17:40:05Z | en_US |
dc.date.issued | 2009-03-01 | en_US |
dc.identifier.citation | Morris, David S.; Weizer, Alon Z.; Ye, Zaojun; Dunn, Rodney L.; Montie, James E.; Hollenbeck, Brent K. (2009). "Understanding bladder cancer death See editorial on pages 914-7, this issue. ." Cancer 115(5): 1011-1020. <http://hdl.handle.net/2027.42/61877> | en_US |
dc.identifier.issn | 0008-543X | en_US |
dc.identifier.issn | 1097-0142 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/61877 | |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=19152434&dopt=citation | en_US |
dc.description.abstract | BACKGROUND: To the authors' knowledge, the extent to which death from bladder cancer is attributable to tumor biology or physician practice patterns is unknown. For this reason, the relative importance of broadening indications for aggressive therapy has unclear implications. METHODS: Patients whose deaths were caused directly by bladder cancer were identified using institutional (n = 126 patients) and administrative (n = 6326 patients) data sources. By using implicit review (clinical data, 2001-2005) and explicit algorithms (Surveillance, Epidemiology, and End Results [SEER]-Medicare, 1992-2002), the authors estimated the proportion of potentially avoidable deaths from bladder cancer. RESULTS: After an implicit review of clinical data, 40 of 126 deaths (31.7%) were classified as potentially avoidable. Compared with those patients who were deemed unsalvageable, these patients generally presented with nonmuscle-invasive disease (80% vs 25.6%; P < .001), received multiple courses of intravesical therapy (32.5% vs 1.2%; P < .001), and had a more protracted course from diagnosis to aggressive treatment (median, 23 months vs 2 months; P < .001). An explicit review of claims data indicated that between 31.6% and 46.8% of the 6326 bladder cancer deaths identified in the SEER-Medicare data potentially were avoidable, depending on the survivorship threshold chosen. Patients whose deaths potentially were avoidable more commonly presented with nonmuscle-invasive disease (66.7% vs 24.7%; P < .0001) and lower grade disease (35.1% vs 15.1%; P < .0001). CONCLUSIONS: The greatest inroads into reducing death from bladder cancer likely hinge on earlier detection or improvement of systemic therapies. However, changing physician practice may translate into nontrivial reductions in bladder cancer mortality. Cancer 2009. © 2009 American Cancer Society. | en_US |
dc.format.extent | 231742 bytes | |
dc.format.extent | 3118 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.publisher | Wiley Subscription Services, Inc., A Wiley Company | en_US |
dc.subject.other | Life and Medical Sciences | en_US |
dc.subject.other | Cancer Research, Oncology and Pathology | en_US |
dc.title | Understanding bladder cancer death See editorial on pages 914-7, this issue. | en_US |
dc.type | Article | en_US |
dc.rights.robots | IndexNoFollow | en_US |
dc.subject.hlbsecondlevel | Oncology and Hematology | en_US |
dc.subject.hlbsecondlevel | Public Health | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | Department of Urology, University of Michigan, Ann Arbor, Michigan | en_US |
dc.contributor.affiliationum | Department of Urology, University of Michigan, Ann Arbor, Michigan | en_US |
dc.contributor.affiliationum | Department of Urology, University of Michigan, Ann Arbor, Michigan | en_US |
dc.contributor.affiliationum | Department of Urology, University of Michigan, Ann Arbor, Michigan | en_US |
dc.contributor.affiliationum | Department of Urology, University of Michigan, Ann Arbor, Michigan | en_US |
dc.contributor.affiliationum | Department of Urology, University of Michigan, Ann Arbor, Michigan ; Fax: (734) 936-9127 ; Department of Urology, Taubman Health Care Center, Room 3875, University of Michigan Health System, 1500 East Medical Center Drive, Ann Arbor, MI 48109-0330 | en_US |
dc.identifier.pmid | 19152434 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/61877/1/24136_ftp.pdf | |
dc.identifier.doi | 10.1002/cncr.24136 | en_US |
dc.identifier.source | Cancer | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.